Adamas Pharmaceuticals INC (ADMS) Shareholder Rhenman & Partners Asset Management Ab Has Lowered Stake by $7.33 Million as Share Value Declined

April 17, 2018 - By Kristen Paramore

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Logo

Rhenman & Partners Asset Management Ab decreased its stake in Adamas Pharmaceuticals Inc (ADMS) by 24.27% based on its latest 2017Q4 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab sold 222,087 shares as the company’s stock declined 31.02% with the market. The institutional investor held 692,913 shares of the health care company at the end of 2017Q4, valued at $23.48 million, down from 915,000 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Adamas Pharmaceuticals Inc for a number of months, seems to be less bullish one the $676.88 million market cap company. The stock increased 3.61% or $0.88 during the last trading session, reaching $25.25. About 269,083 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 35.83% since April 17, 2017 and is uptrending. It has outperformed by 24.28% the S&P500.

Rhenman & Partners Asset Management Ab, which manages about $740.07M US Long portfolio, upped its stake in Humana Inc (NYSE:HUM) by 17,000 shares to 58,000 shares, valued at $14.39 million in 2017Q4, according to the filing. It also increased its holding in Amerisourcebergen Corp (NYSE:ABC) by 94,261 shares in the quarter, for a total of 174,261 shares, and has risen its stake in Sage Therapeutics Inc (NASDAQ:SAGE).

Analysts await Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) to report earnings on May, 8. They expect $-1.32 EPS, down 83.33 % or $0.60 from last year’s $-0.72 per share. After $-1.27 actual EPS reported by Adamas Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 3.94 % negative EPS growth.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage

Among 8 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamas Pharmaceuticals had 13 analyst reports since October 30, 2017 according to SRatingsIntel. As per Wednesday, April 4, the company rating was initiated by Leerink Swann. Mizuho maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) rating on Tuesday, February 20. Mizuho has “Buy” rating and $48.0 target. Needham maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) on Friday, February 23 with “Buy” rating. The company was initiated on Wednesday, November 29 by Northland Capital. On Friday, November 3 the stock rating was maintained by Mizuho with “Buy”. Noble Financial maintained it with “Buy” rating and $48.0 target in Wednesday, November 8 report. Mizuho maintained the stock with “Buy” rating in Tuesday, January 23 report. The rating was maintained by Mizuho with “Buy” on Friday, March 9. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) earned “Buy” rating by Piper Jaffray on Tuesday, January 30. On Thursday, February 22 the stock rating was maintained by Piper Jaffray with “Buy”.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: